ATR inhibitor · small molecule
camonsertib
0 active trials across 2 of our biomarkers, targeting ATR. Not approved for any biomarker on marked.bio yet.
Also known as RP-3500.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
Trials
0 of 1 trials shown
-
RP-6306 in Patients With Advanced Cancer
RP-6306gemcitabineFOLFIRItrastuzumabcamonsertib
Patients must have both a RAS mutation (KRAS) and a TP53 mutation based on local testing\*.
KRAS G12CKRAS G12DAdvanced Cancer
No trials match these filters.